Dr. Bachelot on the Role of Tucatinib in HER2+ Breast Cancer With CNS Metastases
May 7th 2021Thomas Bachelot, MD, PhD, discusses the role of the combination of tucatinib plus trastuzumab and capecitabine in patients with HER2-positive breast cancer who have central nervous system metastases.
Read More